Surna Inc (OTCMKTS:SRNA) Continues to Fall Despite Having Ground Breaking Reflectors in Testing Phase

Surna Inc (OTCMKTS:SRNA) has been continuously registering a decline in the stock market, despite the news from last month that it had successfully made its first shipment of a beta version of its reflectors. The company specializes in indoor cannabis growing technologies. The company completed two weeks of successful shipping of its ground breaking Surna Reflectors. The reflectors are aimed at saving energy and the Surna aims to ship 50 of these to high end cultivation facilities for beta testing. The test locations have been spread over the country and all commercial cultivators participating in the test are state approved. The results of the tests, however, are still awaited.

The reflectors are designed with three different cooling systems; liquid-cooled, vented and forced air. The reflector assists the cultivators with advanced heat transfer and light on target functionalities. This would reduce the indoor growing energy requirements and would make the facility overall energy efficient. The beta versions, however, are all liquid cooled. The other two varieties would be operable on any type of indoor garden facility, regardless of the type of climate control system. The beta reflectors are only capable of functioning with Surna’s own water cooled climate control systems. With the success of these trials the company aims to provide a complete state of the art, energy and cost efficient solution than any of its competitors.

Once the product reaches the line of production, it is expected to take hold in the cannabis industry fairly quick. This would mostly be due to the fact that indoor cannabis growing facilities are considered energy intensive and add stress to the power grid. The government is also on the verge of deciding that these facilities should be charged extra per unit for maintenance of the grid.

Surna Inc (OTCMKTS:SRNA) reported its most recent fall of 13.82% to close at $0.106 on April 13. The company trades 104.39 million shares in the market with a 52-week range of $0.10-$7.75. The results of these trials just might push the stock upwards significantly.

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyrıght 2015 All RIGHTS RESERVED.